Cover Page

Cite item


Today approximately 70% of patients with Hodgkin lymphoma can be cured with the combined-modality therapy. Tumor burden, the importance of which was demonstrated at first 15 years ago, is a powerful prognostic factor. Data of literature of representations on predictive value of Hodgkin’s lymphoma tumor burden are shown in the article. The difficult immunological relations between tumor cells and reactive ones lead to development of the main symptoms. Nevertheless, the collective sign of tumor burden shows the greatest influence on survival and on probability of resistance, which relative risk can be predicted on this variable and treatment program. Patients with bulky disease need escalated therapy with high-dose chemotherapy. Integration into predictive models of the variable will change an expected contribution of clinical and laboratory parameters in the regression analyses constructed on patients with Hodgkin's lymphoma. Today the role of diagnostic functional methods, in particular a positron emission tomography, for metabolic active measurement which allows excluding a reactive component is considered.

About the authors

S. A. Kuleva

N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation
Saint-Petersburg State Pediatric Medical University, Russian Federation

Author for correspondence.
доктор медицинских наук, детский онколог отделения химиотерапии и комби- нированного лечения злокачественных опухолей у детей НИИ онкологии им. Н.Н. Петрова, профессор кафедры онкологии с курсом лучевой диагностики и лучевой терапии СПбГПМУ Адрес: 197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, тел.: +7 (812) 439-95-10 Russian Federation

A. P. Karitskii

N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation

кандидат медицинских наук, главный врач НИИ онкологии им. Н.Н. Петрова Адрес: 197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68, тел.: +7 (812) 439-95-40 Russian Federation


  1. Campo E., Swerdlow S.H., Harris N.L., Pileri S., Stein H., Jaffe E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117 (19): 5019–5032.
  2. Küppers R., Schmitz R., Distler V., Renné C., Bräuninger A., Hansmann M.L. Pathogenesis of Hodgkin’s lymphoma. Eur. J. Haematol. 2005; 75 (Suppl. 66): 26–33.
  3. Steidl C., Connors J.M., Gascoyne R.D. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of microenvironment. J. Clin. Oncol. 2011; 29: 1812–1821.
  4. Hodgkin Th. On some morbid appearances of the absorbent glands and spleen. Med. Chir. Trans. 1832; 17: 68–114.
  5. Connors J.M. Hodgkin’s lymphoma the great teacher. N. Engl. J. Med. 2011; 365: 264–265.
  6. Berg H., Stuve W., Behrendt H. Treatment of Hodgkin’s disease in children with alternating Mechlorethamine, Vincristine, Procarbazine and Prednisone (MOPP) and Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) courses without radiotherapy. Med. Pediatr. Oncol. 1997; 23: 23–27.
  7. Колыгин Б.А., Кулева С.А. Диагностика и лечение лимфомы Ходжкина. СПб.: Гиппократ. 2009. 208 с.
  8. Rathore B., Kadin M.E. Hodgkin’s lymphoma therapy: past, present, and future. Exp. Opin. Pharmacother. 2010; 11 (17): 2891– 2906.
  9. Zander T., Wiedenmann S., Wolf J. Prognostic factors in Hodgkin’s lymphoma. Ann. Oncol. 2002; 13 (1): 67–74.
  10. Josting A. Prognostic factors in Hodgkin Lymphoma. Exp. Rev. Hematol. 2010; 3: 583–592.
  11. Keller A.R., Kaplan H.S., Lukes R.E., Rappaport H. Correlation of histopathology with other prognostic indicators in Hodgkin’s disease. Cancer. 1968; 22: 487–499.
  12. Kaplan H.S. Hodgkin’s disease. Cambridge: Harward University Press. 1980. 689 p.
  13. Кулева С.А., Колыгин Б.А. Прогностические факторы и прогностические модели при лимфоме Ходжкина у детей и подростков. Вопр. онкологии. 2010; 56 (3): 272–277.
  14. Hasenclever D., Diehl V. A prognostic score to predict tumor control in advanced Hodgkin’s disease. N. Engl. J. Med. 1998; 339: 1506–1514.
  15. Cox D. Regression models and life tables. J. R. Stat. Soc. 1972; 34: 187–220.
  16. Eichenauer D.A., Engert A., Dreyling M. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2011; 22 (6): 55–58.
  17. Viviani S., Zinzani P.L., Rambaldi A., Brusamolino E., Levis A., Bonfante V. et al. ABVD versus BEACOPP for Hodgkin’s lymphoma a when high-dose salvage is planned. N. Engl. J. Med. 2011; 365: 203–212.
  18. Kostakoglu L., Gallamini A. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift. J. Nucl. Med. 2013; 54: 1082–1093.
  19. Specht L. Tumor burden as the main indicator of prognostic in Hodgkin’s disease. Eur. J. Cancer. 1992; 28: 1982–1985.
  20. Specht L., Nordentoft A.M., Cold S., Clausen N.T., Nissen N.I. Tumor burden as the most important prognostic factor in early stage Hodgkin’s disease. Relations to other prognostic factors and implications for choice of treatment. Cancer. 1988; 61: 1719–1727.
  21. Specht L., Nissen N.I. Prognostic significance of tumour burden in Hodgkin’s disease PS I and II. Scand. J. Haematol. 1986; 36: 367–375.
  22. Specht L., Nissen N.I. Prognostic factors in Hodgkin’s disease stage III with special reference to tumour burden. Eur. J. Haematol. 1988; 41: 80–87.
  23. Specht L., Nissen N.I. Prognostic factors in Hodgkin’s disease stage IV. Eur. J. Haematol. 1988; 41: 359–367.
  24. Specht L., Nissen N.I. Hodgkin’s disease and stage. Eur. J. Haematol. 1989; 43: 127–135.
  25. Specht L., Lauritzen A.F., Nordentoft A.M., Andersen P.K., Christensen B.E., Hippe E. et al. Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin’s disease. The Danish National Hodgkin Study Group. Cancer. 1990; 65: 2594–2601.
  26. Gobbi P.G., Ghirardelli M.L., Solcia M., Di Giulio G., Merli F., Tavecchia L. et al. Image-aided estimate of tumor burden in Hodgkin’s disease: evidence of its primary prognostic importance. J. Clin. Oncol. 2001; 19: 1388–1394.
  27. Gobbi P.G., Broglia C., Di Giulio G., Mantelli M., Anselmo P., Merli F. et al. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma. Cancer. 2004; 101: 1824–1834.
  28. Straus D.J., Gaynor J.J., Myers J., Merke D.P., Caravelli J., Chapman D. et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially non-cross-resistant chemotherapy and intermediatedose radiation therapy. J. Clin. Oncol. 1990; 7: 1173–1186.
  29. Gobbi P.G., Comelli M., Grignani G.E., Pieresca C., Bertoloni D., Ascari E. Estimate of expected survival at diagnosis in Hodgkin’s disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin’s Disease (IDHD). Haematologica. 1994; 79: 241–255.
  30. Gobbi P.G., Valentino F., Bassi E., Coriani C., Merli F., Bonfante V. et al. Chemoresistence as a function of the pretherapy tumor burden and the chemotherapy regimen administered: difference observed with 2 current chemotherapy regimens for advanced Hodgkin Lymphoma. Clin. Lymphoma Myeloma Leuk. 2011; 11: 396–403.
  31. Gobbi P.G., Bassi E., Bergonzi M., Merli F., Coriani C., Iannitto E. et al. Tumor burden predicts treatment resistance in patients with early unfavorable of advanced stage Hodgkin Lymphoma treated with ABVD and radiotherapy. Hematol. Oncol. 2012; 30: 194–199.
  32. Gobbi P.G., Bergonzi M., Bassi E., Merli F., Coriani F., Frederico M. Tumor burden at diagnosis in the main clinical predictor of cell resistance in patients with early-stage, favorable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. Hematol. Oncol. 2013; 3: 151–155.
  33. Longo D.L., Duffey P.L., Young R.C., Hubbard S.M., Ihde D.C., Glatstein E. et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J. Clin. Oncol. 1992; 10: 210–218.
  34. Gobbi P.G., Bergonzi M., Bassi E., Merli F., Coriani C., Stelitano C. et al. Tumor burden in Hodgkin’s lymphoma can be reliably estimated from a few staging parameters. Oncol. Rep. 2012; 28: 815–820.
  35. Moon S.H., Hyun S.H., Choi J.Y. Prognostic significance of volume-based PET parameters in cancer patients. Korean. J. Radiol. 2013; 14: 1–12.
  36. Merli F., Luminari S., Coriani C. FDG-PET and Hodgkin lymphoma: are we ready for a functional tumor volume definition? (ASH Annual Meeting 2011). Blood. 2011; 118: 5187.

Comments on this article

Copyright (c) 1970 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies